Innovate

October 11, 2016

Double Duty

In the past, women requiring mastectomy for breast cancer typically faced a series of operations and recoveries. But now patients may be able to opt for simultaneous surgeries, which can give better cosmetic results including less scarring. Before undergoing any type of breast reconstruction surgery, it’s important understand what it involves and get answers to […]

Read More

September 14, 2016

Lymphoma, Leukemia, Myeloma: Hope on the Horizon

Advances in diagnosing and treating blood cancers have helped double survival rates, and the future outlook may be even brighter. Blood cancers—lymphoma, leukemia and myeloma—made up almost 10 percent of all cancer cases diagnosed in 2015, or about 162,000 new cancer cases. At the same time, progress is being made on the survival front. More […]

Read More

August 4, 2016

Playing Defense

You probably think of your immune system as your body’s natural defense against external infections, or that thing you try to boost during flu season. But as a former laboratory researcher who explored using the immune system to fight diseases, I’ve seen firsthand how its elegant signaling pathways can be modified to better fight cancer. […]

Read More

August 4, 2016

Precision Treatment: Studies Show Hope on the Horizon

The Claim:  Patients who received precision treatment—in which doctors used drugs targeting their specific DNA mutations—saw tumor shrinkage at rates six times greater than those who were given regular chemotherapy. The interval of time before their cancer continued growing was also nearly twice as long. The Study: Researchers at the University of California, San Diego Health […]

Read More

May 24, 2016

Immunotherapy: Studies Show Hope on the Horizon

The Claim: The body’s immune system can be activated to combat certain tumors—including sarcomas, cancers that occur in connective tissues—using a combination of immunotherapy and chemotherapy. The Study: In Phase I of the PembroPlus study that began in January 2015, pembrolizumab was administered to a small group of patients to evaluate its safety, determine safe […]

Read More

May 23, 2016

B-12 Deficiencies: Studies Show Hope on the Horizon

The Claim: Evaluating methylmalonic acid (MMA) and homocysteine (HC) rather than vitamin B-12 alone can better identify cancer patients with functional B-12 deficiencies. The Study: In 2014, a group of 316 patients at Cancer Treatment Centers of America® at Midwestern Regional Medical Center were tested. All patients were evaluated at baseline for vitamin B-12, methylmalonic […]

Read More

May 23, 2016

The Missing LinQ: Technology on the Horizon

Big data gives us a mountain of facts and figures. Our challenge: putting that information to use in a way that improves patient care—now and for years to come. CancerLinQ™, a new initiative from the American Society of Clinical Oncology (ASCO), is a technology platform that allows large amounts of anonymous health care data to […]

Read More

February 19, 2016

Ahead of the Curve

Clinical trials are often seen as a beacon of hope—even for those battling stage IV cancers. Participating in clinical trials is a way to gain access to drugs and therapies years before they’re approved for commercial use. If successful, these innovations may help you heal and set the course for the successful treatment of other […]

Read More

December 20, 2015

An ‘Achilles Heel’ in Common Cancer Gene Mutation

The protein K-Ras is the most commonly mutated oncogene in human cancers. Because of this notorious reputation, researchers have been trying, unsuccessfully, for three decades to develop a drug that might inhibit it. Targeting K-Ras has proved so elusive that the scientific community has dubbed it “undruggable” – a moniker that may now have to […]

Read More

November 16, 2015

New Genetic Test Uncovers Men at 10-Fold Increased Risk of Testicular Cancer

Testicular cancer is relatively rare, affecting just one out of every 263 U.S. men. However, it’s one of the most common cancers among young men; the average age at time of diagnosis is 33 years. Testicular cancer is highly treatable, such that a man’s lifetime risk of dying from this disease is very low (about […]

Read More
1 2 3 4 5